TY - JOUR
T1 - Identification of novel biomarkers for behcet disease diagnosis using human proteome microarray approach
AU - Hu, Chao Jun
AU - Pan, Jian Bo
AU - Song, Guang
AU - Wen, Xiao Ting
AU - Wu, Zi Yan
AU - Chen, Si
AU - Mo, Wen Xiu
AU - Zhang, Feng Chun
AU - Qian, Jiang
AU - Zhu, Heng
AU - Li, Yong Zhe
N1 - Funding Information:
This work was supported by the National Natural Science Foundation of China Grants No. 81373188, 81172857 (to YZ. L.), 81302610 to (to ChJ. H.), the Chinese National High Technology Research and Development Program, Ministry of Science and Technology Grants No. 2011AA02A113, the National Science Technology Pillar Program in the 12nd Five-year Plan No. 2014BAI07B00, the capital health research and development of special grants No. 2014-1-4011 (to YZ. L.). Youth Research Foundation of Peking Union Medical College No. 3332015091 (to ChJ. H.).
Publisher Copyright:
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.
PY - 2017/2
Y1 - 2017/2
N2 - Behcet disease (BD) is a chronic systemic vasculitis and considered as an autoimmune disease. Although rare, BD can be fatal due to ruptured vascular aneurysms or severe neurological complications. To date, no known biomarker has been reported for this disease, making it difficult to diagnosis in the clinics. To undertake this challenge, we employed the HuProt arrays, each comprised of ∼20,000 unique human proteins, to identify BD-specific autoantibodies using a Two-Phase strategy established previously. In Phase I, we profiled the autoimmunity on the HuProt arrays with 75 serum samples collected from 40 BD patients, 15 diagnosed autoimmune patients who suffer from Takayasu arteritis (TA; n = 5)), ANCA associated vasculitis (AAV; n = 5), and Sjogren's syndrome (SS; n = 5), and 20 healthy subjects, and identified 20 candidate autoantigens that were significantly associated with BD. To validate these candidates, in Phase II we constructed a focused array with these 20 candidate BD-associated antigens, and use it to profile a much larger cohort, comprised of serum samples collected from 130 BD patients, 103 autoimmune patients (i.e. 40TA, 40 AAV and 23 SS), and 110 healthy controls. This allowed us to validate CTDP1 (RNA polymerase II subunit A C-terminal domain phosphatase)as a BD-specific autoantigen. The association of anti-CTDP1 with BD patients was further validated using the traditional Western blotting analysis. In conclusion, anti-CTDP1 antibody serves a novel autoantibody for Behcet disease and is expected to help more accurate clinical diagnosis.
AB - Behcet disease (BD) is a chronic systemic vasculitis and considered as an autoimmune disease. Although rare, BD can be fatal due to ruptured vascular aneurysms or severe neurological complications. To date, no known biomarker has been reported for this disease, making it difficult to diagnosis in the clinics. To undertake this challenge, we employed the HuProt arrays, each comprised of ∼20,000 unique human proteins, to identify BD-specific autoantibodies using a Two-Phase strategy established previously. In Phase I, we profiled the autoimmunity on the HuProt arrays with 75 serum samples collected from 40 BD patients, 15 diagnosed autoimmune patients who suffer from Takayasu arteritis (TA; n = 5)), ANCA associated vasculitis (AAV; n = 5), and Sjogren's syndrome (SS; n = 5), and 20 healthy subjects, and identified 20 candidate autoantigens that were significantly associated with BD. To validate these candidates, in Phase II we constructed a focused array with these 20 candidate BD-associated antigens, and use it to profile a much larger cohort, comprised of serum samples collected from 130 BD patients, 103 autoimmune patients (i.e. 40TA, 40 AAV and 23 SS), and 110 healthy controls. This allowed us to validate CTDP1 (RNA polymerase II subunit A C-terminal domain phosphatase)as a BD-specific autoantigen. The association of anti-CTDP1 with BD patients was further validated using the traditional Western blotting analysis. In conclusion, anti-CTDP1 antibody serves a novel autoantibody for Behcet disease and is expected to help more accurate clinical diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=85013177870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013177870&partnerID=8YFLogxK
U2 - 10.1074/mcp.M116.061002
DO - 10.1074/mcp.M116.061002
M3 - Article
C2 - 27777341
AN - SCOPUS:85013177870
SN - 1535-9476
VL - 16
SP - 147
EP - 156
JO - Molecular and Cellular Proteomics
JF - Molecular and Cellular Proteomics
IS - 2
ER -